2 3
Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla 24 3
6 3
28 3
DISEASE NIH Study ID DESCRIPTION Bone Metastases Breast Cancer Breast Cancer Cervical Cancer Colon Cancer Endometrial Cancer Leukemia NCT00869206 NCT01439282 NCT01421472 NCT00980954 NCT01150045 NCT00807768 NCT01414205 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination with Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer A Randomized, Phase II Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High-Risk, Early-Stage Endometrial Carcinoma An Open-Label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1,000 mg Versus 2,000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia Leukemia NCT01244750 Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-year Prospective Cohort Study (SIMPLICITY) Lung Cancer Lung Cancer Lymphoma Melanoma Ovarian Cancer Prostate Cancer Renal Cancer NCT01204099 NCT00693992 NCT01294579 NCT01120275 NCT01167712 NCT01312974 NCT01441414 Phase I/II Study of PX-866 and Docetaxel in Patients With Solid Tumors Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin s Lymphoma (B-NHL) Which Has Relapsed After Rituximab Therapy A Phase III Randomized Study of Four Weeks of High Dose IFN-alpha2b in Stage T2b N0, T3a-b N0, T4a-b N0 and T1-4 N1a-2a (Microscopic) Melanoma A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose-Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab (Nsc #704865, Ind #7921) In The Treatment Of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Support) in Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Inhibitor In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma 10
12
14
16
18
National Quality Forum (NQF) specifications of the breast, colon and rectal cancer care measures Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer (BCS/RT). Performance Rates 2008 YVMH Hosp WA State All Other 98.6% 89.7% 88% Case Review BCS/ RT % Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer (MAC). Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer (HT). Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age 80 with AJCC Stage III (lymph node positive) colon cancer (ACT). At least 12 regional lymph nodes are removed and pathologically examined for surgically resected colon cancer (12 RLN). Adjuvant radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer (AdjRT). 100% 89.7% 88.2% MAC 97.6% 85.1% 82% HT 100% 91.2% 88.9% ACT 85.7% 85.5% 82.7% 12 RLN 100% 91.1% 89.5% AdjRT 20 %
18 22 3
24
26
Cancer Care Center A Home for Hospice Care